image credit: Unsplash

Lilly’s Retevmo cleared for RET-positive child cancers

May 30, 2024


Retevmo (selpercatinib) can now be used to treat RET-positive thyroid cancers and other solid tumours with the mutation, regardless of their type.

Specifically, the new indication covers advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, advanced or metastatic thyroid cancer with a RET gene fusion that can’t be treated with radioactive iodine therapy, and locally advanced or metastatic solid tumours with a RET gene fusion that have progressed after prior systemic treatment or have no treatment options.

Read More on Pharmaphorum